Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Biologic therapy.

US Oncology Research Inc, The Woodlands, TX, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:The Woodlands, TX
Treatments:Biologic therapyHospital:US Oncology Research Inc
Drugs:Journal:Link
Date:Jan 2010

Description:

Patients:
This phase 2 study involved 60 relapsed or refractory indolent lymphoma patients who were previously treated with rituximab. The median patient age was 70 years and 47% were male.

Treatment:
Patients were treated with the biologic therapy agent called bortezomib, which is classified as a proteasome inhibitor and interferes with cancer cell growth.

Toxicities:
The most severe toxicities were of grade 4 and included thrombocytopenia and dehydration. Grade 3 neutropenia, fatigue, and diarrhea were also reported.

Results:
The median overall survival was 27.7 months.

Support:
This work was partially supported by Millennium Pharmaceuticals Inc.

Correspondence: Dr. Nicholas Di Bella; email: [email protected]



Back